Our results indicate that both Rab32 and Rab38 may serve as drug targets for suppressing osteoclast function and may be developed like a bisphosphonate or like odanacatib, a CTSK inhibitor, as a therapeutic agent for rheumatoid arthritis, osteoporosis, and periodontitis. Here, RAB32 is linked to periodontitis.